When will the patents on LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE expire, and when will generic LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE be available?

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A
FHI 360	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xiromed	LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	214640-001	Aug 16, 2023	AB3	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 20, 2026

Levonorgestrel, ethinyl estradiol, and ferrous fumarate is a mature extended-cycle oral contraceptive product category. The original branded product, Seasonique, established the 91-day regimen of 84 hormonal tablets followed by seven ferrous fumarate tablets. The market has since shifted toward generic substitution, payer-driven formulary competition, and low-cost pharmacy distribution.

The category has durable demand because oral contraception remains a large U.S. outpatient market. Its financial profile is less attractive than that of newer contraceptive products because the active ingredients are off-patent, multiple generic manufacturers compete, and individual-product revenue is generally not disclosed by manufacturers.

What is levonorgestrel and ethinyl estradiol and ferrous fumarate?

Levonorgestrel and ethinyl estradiol and ferrous fumarate is an extended-cycle combined oral contraceptive. The hormonal tablets contain:

Levonorgestrel, a progestin
Ethinyl estradiol, an estrogen
Ferrous fumarate, an iron supplement included in the non-hormonal tablets

The commonly marketed 91-day regimen contains 84 active tablets and seven ferrous fumarate tablets. Ferrous fumarate does not provide contraceptive activity. It is included as part of the tablet sequence during the scheduled hormone-free interval.

Seasonique was approved by the FDA in 2006 under NDA 021910. The product was developed by Duramed Pharmaceuticals, later acquired by Barr Pharmaceuticals, which was acquired by Teva Pharmaceutical Industries in 2008. [1,2]

Which products compete with Seasonique?

The principal products and related formulations include:

Product	Hormonal regimen	Iron tablets	Market position
Seasonique	0.15 mg levonorgestrel / 0.03 mg ethinyl estradiol	Ferrous fumarate	Original branded extended-cycle product
Generic Seasonique equivalents	Same or therapeutically equivalent 91-day regimen	Usually included	Main source of price competition
LoSeasonique	Lower estrogen formulation	Ferrous fumarate	Lower-dose extended-cycle alternative
Amethia and related products	Extended-cycle levonorgestrel/ethinyl estradiol	Product-dependent	Generic and authorized-generic competition
Jolessa and similar products	Extended-cycle levonorgestrel/ethinyl estradiol	Generally no iron tablets	Therapeutic substitute, not an identical formulation
Other combined oral contraceptives	Monthly or extended-cycle regimens	Usually none	Broader category substitutes

Product availability varies by manufacturer, pharmacy channel, payer formulary, and FDA marketing status.

How large is the market for this oral contraceptive category?

The product competes within the much larger U.S. combined oral contraceptive market rather than operating as a standalone high-growth pharmaceutical segment. Demand is supported by:

Continued use of oral contraception among reproductive-age patients.
Preference among some patients for fewer scheduled withdrawal bleeds.
Low manufacturing complexity for conventional compressed tablets.
Broad retail-pharmacy distribution.
Prescriber familiarity with levonorgestrel and ethinyl estradiol.

The commercial market is highly fragmented. Revenue is distributed among branded products, authorized generics, ANDA-approved generics, pharmacy benefit managers, wholesalers, and retail pharmacies. Manufacturers do not generally report revenue for the specific levonorgestrel/ethinyl estradiol/ferrous fumarate combination.

Public company filings typically aggregate oral contraceptive sales within broader women’s health, generic pharmaceuticals, or North American commercial portfolios. Teva, for example, reports at business-segment and major-product levels rather than providing a separate current revenue line for Seasonique or its generic equivalents. [3]

What is the financial trajectory of Seasonique and generic equivalents?

The financial trajectory follows a standard mature-product pattern:

Period	Commercial development	Financial effect
2006-2008	Seasonique launches as a branded extended-cycle contraceptive	Premium pricing and differentiated regimen
2008-2012	Teva ownership and broader distribution	Greater scale, but increasing substitution pressure
2010s	Generic approvals and formulary substitution	Rapid erosion in branded net price and share
2020s	Mature generic market with multiple suppliers	Low unit economics, stable but price-sensitive demand
Forward outlook	Continued commodity competition	Volume stability with limited pricing power

Branded sales typically decline after generic entry because oral contraceptives are readily substitutable and payers can mandate generic dispensing. Net revenue can fall faster than prescription volume because rebates, copay programs, and formulary concessions reduce realized price.

The financial value of the product today is more likely to come from portfolio scale, manufacturing efficiency, and channel access than from proprietary pricing. A manufacturer with an established oral-solid-dose plant and retail distribution can still earn returns at low prices, but the product is unlikely to support meaningful premium pricing without a differentiated delivery system, brand positioning, or payer advantage.

Is product-specific revenue publicly available?

No reliable public financial series isolates levonorgestrel/ethinyl estradiol/ferrous fumarate revenue across all manufacturers. The market includes products sold under different labels, national drug codes, manufacturers, and dosage strengths. Prescription volume and sales estimates from commercial databases such as IQVIA or Symphony Health are generally proprietary.

Reported revenue should therefore be assessed at the manufacturer or contraceptive-portfolio level. At the product level, useful indicators include:

Prescription volume
Average wholesale price and acquisition cost
Generic manufacturer count
Medicaid and commercial formulary placement
Retail versus mail-order share
FDA-approved suppliers
Product discontinuation notices
Wholesaler inventory and back-order activity

What drives market demand for this contraceptive?

Extended-cycle dosing

The 91-day regimen is the main commercial differentiator. Patients take active hormonal tablets for approximately 12 weeks before the scheduled low-hormone or iron-tablet interval. This can reduce the frequency of scheduled withdrawal bleeding compared with traditional 28-day regimens.

The benefit is behavioral and convenience-oriented rather than a new pharmacologic mechanism. That makes the product relatively easy to substitute with other extended-cycle combined oral contraceptives.

Low-cost access

Generic availability has made cost a primary market driver. Many payers treat generic levonorgestrel/ethinyl estradiol products as preferred options. Brand products may require prior authorization or higher copay tiers unless the prescriber documents clinical need.

The FDA’s contraceptive coverage framework under the Affordable Care Act also affects patient access, although coverage is determined by plan design, exemptions, state requirements, and applicable federal policy. [4]

Established clinical profile

Levonorgestrel is a well-established progestin with extensive clinical use. The product does not require cold-chain distribution, specialty pharmacy handling, or patient training. These factors support broad pharmacy dispensing and low commercial overhead.

What regulatory status does the product have?

The product is regulated as a prescription combined hormonal contraceptive. Seasonique received FDA approval under NDA 021910. Generic versions are approved through the abbreviated new drug application pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product. [1,5]

The main regulatory requirements concern:

Hormonal content and tablet sequencing
Bioequivalence
Stability and shelf life
Packaging that prevents tablet-order errors
Labeling for thrombotic and cardiovascular risks
Manufacturing controls
Patient instructions for missed tablets

The FDA labeling identifies important contraindications, including a history of thrombosis, certain cardiovascular conditions, migraine with aura, uncontrolled hypertension, and smoking in older patients. The CDC U.S. Medical Eligibility Criteria provides condition-specific guidance for contraceptive use. [6]

What patents protect levonorgestrel and ethinyl estradiol and ferrous fumarate?

The active ingredients are longstanding and do not provide meaningful composition-of-matter exclusivity. Any remaining intellectual-property value would generally arise from:

Specific extended-cycle dosing schedules
Tablet sequencing
Formulation or manufacturing processes
Packaging systems
Method-of-use claims
Product-specific labeling

The original Seasonique patent estate is no longer the primary commercial barrier to generic entry. The key competitive issue is FDA approval and commercial scale, not basic molecule ownership.

Are formulation patents still commercially important?

Formulation and regimen patents can delay or complicate generic entry when they cover a commercially necessary feature. Their practical value declines when:

The claims expire.
Generic applicants can design around the claims.
The FDA approves an alternative reference product.
Several suppliers enter the market.
Payers accept therapeutically substitutable products.

For this category, generic entry risk is structurally high because the product is a conventional oral tablet and the ingredients are well characterized.

Are method-of-use patents material?

Method-of-use claims may cover reduction in menstrual frequency or use of an extended-cycle contraceptive regimen. Such claims rarely create a durable commercial moat after the underlying product and formulation patents expire. They can affect labeling and litigation strategy, but they are less likely to support premium pricing in a crowded oral-contraceptive market.

Are there Paragraph IV challenges or patent litigation risks?

Paragraph IV litigation is most relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. The risk profile for Seasonique-type products has diminished as the original intellectual-property term has aged and generic alternatives have entered the market.

Current commercial risk is more likely to involve:

Manufacturing compliance
Product recalls
Supply interruptions
Labeling disputes
Abbreviated new drug application approval timing
State substitution rules
Contracting with pharmacy benefit managers

A definitive current litigation conclusion requires a live review of FDA Orange Book listings, ANDA status, district-court dockets, and the Federal Circuit docket. The existence of an old patent listing does not by itself establish an enforceable barrier to generic launch.

What is the Orange Book status of Seasonique?

The FDA Orange Book is the controlling source for listed patents, exclusivity codes, therapeutic-equivalence evaluations, and reference-product information. [5]

The relevant review points are:

Orange Book issue	Commercial relevance
Reference listed drug status	Determines the product used for generic comparison
Patent listings	Identifies patents submitted by the NDA holder
Exclusivity codes	Shows whether regulatory exclusivity remains
Therapeutic-equivalence rating	Supports pharmacy substitution
Marketing status	Indicates whether the listed product remains actively marketed

For a mature product such as Seasonique, any remaining listing should be assessed against expiration, delisting, litigation history, and the existence of approved therapeutically equivalent products. Orange Book status should not be confused with active brand demand or patent enforceability.

When does levonorgestrel and ethinyl estradiol and ferrous fumarate lose exclusivity?

The active ingredients lost basic exclusivity many years ago. The commercial loss of exclusivity occurred through the expiration of product-specific protection and subsequent generic approvals, rather than through a single current cliff.

The relevant timeline is:

Drug substance exclusivity: expired long ago.
Original Seasonique regulatory exclusivity: expired.
Product-specific patent protection: no longer the central market barrier.
Generic competition: established.
Current market structure: mature, multi-supplier, price competitive.

FDA regulatory exclusivity and patent protection are separate. A product can have no remaining regulatory exclusivity while still carrying listed patents, and a patent listing does not guarantee enforceability.

Is there biosimilar risk for this product?

There is no biosimilar risk. Biosimilars apply to biological products, while levonorgestrel and ethinyl estradiol and ferrous fumarate is a conventional chemically synthesized oral drug.

The relevant competitive threats are:

ANDA-approved generics
Authorized generics
Other combined oral contraceptives
Progestin-only pills
Long-acting reversible contraceptives
Over-the-counter contraceptive products

The FDA approved Opill, a norgestrel progestin-only oral contraceptive, as the first nonprescription daily oral contraceptive in the United States in 2023. Opill does not contain ethinyl estradiol and therefore is not a direct pharmaceutical equivalent, but it expands consumer access and increases competitive pressure within the oral-contraception category. [7]

How does this product compare with newer contraceptive options?

Attribute	Levonorgestrel/ethinyl estradiol/ferrous fumarate	Progestin-only pill	Long-acting reversible contraceptive
Administration	Daily oral tablet	Daily oral tablet	Device or injection
Estrogen exposure	Yes	No	Depends on product
Extended-cycle option	Yes	Product-specific	Not based on monthly pill cycle
Retail availability	Broad	Expanding	Provider-dependent
Generic competition	High	Increasing	Varies by device
Adherence dependence	High	High	Lower after placement
Manufacturing complexity	Low	Low	Higher
Pricing power	Limited	Limited to moderate	Greater for branded devices

The main weakness of the extended-cycle combination is daily adherence. Long-acting products may deliver stronger clinical persistence but involve procedures, higher acquisition costs, and different reimbursement economics.

What licensing deals affect the product?

The key historical transaction was Teva’s acquisition of Barr Pharmaceuticals in 2008. Barr had acquired Duramed Pharmaceuticals, the original developer and marketer associated with Seasonique. [2]

No major current licensing structure is publicly associated with the core product category. Generic products are generally supplied through manufacturer, distributor, and pharmacy contracting arrangements rather than high-value licensing agreements. Commercial value is concentrated in regulatory approvals, manufacturing capacity, and payer access.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are modest but not negligible. Suppliers must reliably produce multiple tablet types, maintain correct sequence and labeling, and meet quality standards across a long-cycle package.

The most relevant operational risks are:

Hormonal-content variability
Tablet-ordering and packaging errors
Supply of ferrous fumarate tablets
Finished-dose manufacturing capacity
FDA inspection findings
Packaging-component shortages
Product recalls
Retail back-order exposure

These barriers can temporarily improve pricing for a constrained supplier, but they do not create durable protection comparable to a patented drug-delivery platform.

What generic launch scenarios are most likely?

Base case: continued price erosion

Multiple generic suppliers remain active. Prescription volume is stable or modestly declining, while net price falls through payer substitution and pharmacy purchasing pressure.

Upside case: supply consolidation

If several manufacturers discontinue the product or experience manufacturing problems, remaining suppliers may gain volume and temporary pricing leverage. This would be a supply event, not a patent-driven recovery.

Downside case: substitution by other contraceptives

Patients and prescribers may shift toward progestin-only pills, long-acting contraceptives, monthly combination pills, or over-the-counter oral contraception. The effect would be gradual because the category remains clinically established.

How strong is the patent estate?

The patent estate is weak as a current commercial moat. The ingredients are old, the regimen is established, and generic competition is present. Residual intellectual-property value may remain in specific formulations, packaging, or method-of-use claims, but these claims are unlikely to support substantial long-term pricing power.

The stronger assets are operational:

FDA-approved product dossiers
Reliable supply
Low-cost production
National wholesaler access
Payer contracts
Pharmacy substitution status

Key Takeaways

Levonorgestrel and ethinyl estradiol and ferrous fumarate is a mature extended-cycle oral contraceptive category.
Seasonique was the original branded product and was approved by the FDA in 2006.
Generic competition has shifted value from patent exclusivity to manufacturing scale and payer access.
Product-specific revenue is not separately disclosed by major manufacturers.
The market has stable underlying demand but limited pricing power.
There is no biosimilar risk because the product is a conventional small-molecule drug.
The main competitive threats are generic oral contraceptives, progestin-only pills, long-acting contraceptives, and over-the-counter products such as Opill.
Current investment risk is more closely tied to supply reliability, formulary access, and portfolio economics than to patent litigation.

FAQs

Is Seasonique still a profitable pharmaceutical product?

It can remain profitable as a low-cost generic or mature portfolio product, but it is unlikely to generate the margins associated with an innovative branded medicine.

Does ferrous fumarate make Seasonique clinically different from other extended-cycle contraceptives?

Ferrous fumarate distinguishes the tablet sequence, but it is not the contraceptive component. Its inclusion does not create a separate contraceptive mechanism.

Can a generic manufacturer launch without copying the ferrous fumarate tablets?

A generic manufacturer must match the approved product’s relevant dosage form and regimen requirements, but its formulation and inactive ingredients may differ if FDA equivalence requirements are satisfied.

Is this product affected by the FDA approval of Opill?

Yes, indirectly. Opill expands the oral-contraception market and may divert some patients from estrogen-containing pills, although it is not therapeutically equivalent to the levonorgestrel/ethinyl estradiol combination.

What is the most important commercial metric for this product?

Net realized price after rebates and payer discounts is usually more important than list price. Generic supplier count, prescription volume, and formulary placement are the next most important indicators.

References

U.S. Food and Drug Administration. (2006). Seasonique: Prescribing information, NDA 021910.
Teva Pharmaceutical Industries Ltd. (2008). Teva completes acquisition of Barr Pharmaceuticals.
Teva Pharmaceutical Industries Ltd. (2024). Annual report for the year ended December 31, 2023.
U.S. Department of Health and Human Services. (n.d.). Birth control benefits and reproductive health care options.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Centers for Disease Control and Prevention. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73(4).
U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE at DailyMed

AI Deep Research

Questions you can ask:

Summary for LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Recent Clinical Trials for LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE